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Dose-escalationa b s t r a c t
Purpose: This study investigates the feasibility and potential benefits of radiotherapy with a 1.5 T MR-
Linac for locally advanced non-small cell lung cancer (LA NSCLC) patients.
Material and methods: Ten patients with LA NSCLC were retrospectively re-planned six times: three treat-
ment plans were created according to a protocol for conventionally fractionated radiotherapy and three
treatment plans following guidelines for isotoxic target dose escalation. In each case, two plans were
designed for the MR-Linac, either with standard (7 mm) or reduced (3 mm) planning target volume
(PTV) margins, while one conventional linac plan was created with standard margins. Treatment plan
quality was evaluated using dose–volume metrics or by quantifying dose escalation potential.
Results: All generated treatment plans fulfilled their respective planning constraints. For conventionally
fractionated treatments, MR-Linac plans with standard margins had slightly increased skin dose when
compared to conventional linac plans. Using reduced margins alleviated this issue and decreased expo-
sure of several other organs-at-risk (OAR). Reduced margins also enabled increased isotoxic target dose
escalation.
Conclusion: It is feasible to generate treatment plans for LA NSCLC patients on a 1.5 T MR-Linac. Margin
reduction, facilitated by an envisioned MRI-guided workflow, enables increased OAR sparing and isotoxic
target dose escalation for the respective treatment approaches.
 2017 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology xxx (2017) xxx–xxx
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Current survival rates for patients with locally advanced non-
small cell lung cancer (LA NSCLC) are poor [1,2]. In spite of
improvements in both radiotherapy technology and systemic ther-
apies, some suggest that current treatment strategies have reached
their therapeutic ceiling [3]. Effective local disease control is essen-
tial for the survival of these patients [1]. Taking heed from stereo-
tactic radiotherapy for early-stage NSCLC patients, where
biologically equivalent doses of 100 Gy and more result in local
disease control rates greater than 90% [4], dose intensification con-
tinues to be investigated in LA NSCLC patients. Indiscriminate tar-
get dose escalation, delivered with a prolonged overall treatmentcourse, may be detrimental [5,6]. However, data have shown
promising outcomes in LA NSCLC patients treated with accelerated
isotoxic dose-escalated radiotherapy [7–11], where each patient
was prescribed an individualized target dose, escalated on the
basis of normal-tissue tolerances up to a trial-specific maximum
target dose [3].
During a course of radical radiotherapy for LA NSCLC patients,
there can be substantial inter- and intra-fractional changes in tho-
racic anatomy, due to respiratory and cardiac motion, patient
weight loss, tumour growth or shrinkage, or changes in the
surrounding lung [12,13]. Daily cone-beam CT scans are utilized
to set patients up according to the observed tumour position and
any remaining uncertainties are accounted for using planning
target volume (PTV) margins. However, large margins result in
increased irradiation of healthy tissue and restrict isotoxic target
dose escalation.
Recently, MRI-guided treatment units have emerged, allowing
acquisition of MR images immediately prior to and duringeld and
oi.org/
2 Treating locally advanced lung cancer with a 1.5 T MR-Linacradiotherapy delivery [14–17]. The availability of these images
with improved soft-tissue contrast may increase target delineation
reproducibility, as has been shown for other tumour sites, and
reduce setup uncertainties [18–20]. Integrating MRI-guided units
into clinical practice has implications for treatment planning as
treatments will be delivered within a static magnetic field. These
differ from the ones delivered at zero magnetic field because the
trajectories of secondary electrons are altered by the Lorentz force
[21,22] and may cause local increases in dose (‘‘hot spots”), espe-
cially at air-tissue-interfaces, where electrons can loop around
and deposit energy at the surface they have been ejected from
[23]. Furthermore, the irradiation geometry and beam energy of
MRI-guided units deviate from the ones realized for conventional
linacs.
Several studies have evaluated the effect of magnetic fields and
irradiation geometry on stereotactic radiotherapy of early-stage
NSCLC [24–29]. However, none have specifically investigated the
use of MRI-guided units for treatment of patients with LA NSCLC.
This study used an isotoxic dose-escalated trial protocol as well
as a conventionally fractionated scheme to generate treatment
plans for a conventional linac and plans for a 1.5 T MR-Linac using
standard or reduced margins. By comparing the planned dose
distributions we explored the hypothesis that it is feasible to create
clinically acceptable radiotherapy plans for the MR-Linac.
Furthermore, the effect of reducing PTV margins with regard to
sparing of healthy tissue and potential target dose escalation was
investigated.Material and methods
Patient datasets and contouring
For this study we used treatment planning 4DCT scans of ten
consecutive patients undergoing radical radiotherapy for LA NSCLC
at our institution. The scans were acquired using a Philips Bril-
liance CT Big Bore scanner (Philips Medical Systems, Best, the
Netherlands) with a voxel size of 1  1  2 mm3. Details of the
patient characteristics can be found in the Supplemental material.
All patients had given written, informed consent for their scans to
be used for research purposes.
One clinician contoured the gross tumour volume (GTV) on
each of the ten phases of the 4DCT scan. In order to account for
microscopic disease spread, each GTV contour was expanded
isotropically by 5 mm to derive the clinical target volumes (CTV).
Afterwards, the union of the CTV contours was used to create the
internal target volume (ITV) on the average CT image, which was
derived from the 4D acquisition.
Two different margin approaches were used to calculate the
planning target volume (PTV). Standard PTV margins expanded
the ITV by approximately 7 mm, depending on direction, and emu-
late the clinical standard at our institution. A smaller PTV using
reduced margins of approximately 3 mm was also created. This
was motivated by the potential reduction of treatment uncertain-
ties with the envisioned MR-Linac workflow that would incorpo-
rate patient imaging, delineation of critical structures and
adaptation of the treatment plan before each fraction [30]. We
assume that the use of MR images with high soft-tissue contrast
allows for more accurate target delineation and localization. Addi-
tionally, a future MR-Linac workflow could potentially incorporate
plan re-optimization for each fraction and allow adaptation of the
ITV to inter-fractional changes in tumour motion magnitude. Both
PTV margins were calculated using van Herk’s margin recipe and
Table 1 summarizes the individual error contributions, which were
either derived from clinical judgment or taken from the literature
[31,32]. While this approach disregards the contouring accuracy
on MR images depending on the position of the tumour relativePlease cite this article in press as: Bainbridge HE et al. Treating locally advan
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the scope of this study.
The mediastinal envelope, heart, oesophagus, brachial plexus,
spinal canal, skin and lungs were delineated on the average CT
image. The lung structure was defined as both lungs minus the
union of all GTV contours. The skin was defined as the 5 mm rind
of the patient contour.Treatment planning technique and machine models
All treatment plans were designed using the Monaco treatment
planning system (Elekta AB, Stockholm, Sweden), research version
5.19.02. Monaco allows for treatment plan optimization and dose
calculation under consideration of the magnetic field. Its dose cal-
culation also accounts for the irradiation geometry of the proto-
type of the 1.5 T MR-Linac, such as the specific beam energy,
beam filtration, fixed isocenter, source-to-axis distance and the
MLC leaf width at isocenter. Key differences to the conventional
Elekta Versa HD linac are provided in Table 2.
For each patient case, we designed treatment plans following
two different protocols. One set of plans was designed according
to a conventional fractionation protocol with 55 Gy in 20 fractions.
The other plans were created based on the United Kingdom iso-
toxic intensity modulated radiotherapy (IMRT) trial protocol that
allows for isotoxic target dose escalation up to 79.2 Gy in 44 frac-
tions (treating twice daily) by increasing the number of 1.8 Gy frac-
tions until an organ-at-risk (OAR) constraint is reached [33]. For
this study, we adapted the protocol and removed the artificial limit
on maximum target prescription dose. Planning guidelines for both
protocols can be found in the Supplemental material. For each of
the two planning approaches, three plans were generated: one
for the conventional Versa HD linac without a beam flattening filter
and two for the MR-Linac. Treatment plans for the MR-Linac were
designed with either standard or reduced PTV margins, whereas
plans for the conventional linac were generated using standard
PTV margins.
All plans were generated using step-and-shoot IMRT with nine
equidistant, coplanar beams. The beam isocenter was positioned at
the centre of the ITV for the conventional linac treatment plans and
fixed at the centre of the MR bore, 13 cm above the treatment
couch’s surface for the MR-Linac plans. In order to ensure compa-
rability of all plans, the plans were scaled so that the mean ITV
dose was equal to the respective prescription level. Additionally,
we used similar optimization functions and equal plan modulation
options for all treatment plans per respective treatment protocol.
All dose distributions were calculated as dose-to-medium dose
using Elekta’s Monte Carlo engine based on work by Hissoiny
et al. [34] with a statistical dose uncertainty of 2% per calculation
on a dose grid of 0.25  0.25  0.25 cm3.Plan evaluation
For each patient, the dose to OAR and potential for target dose
escalation calculated for the conventional linac was compared to
that for the MR-Linac with standard margins to investigate the
effect of the different irradiation geometries. Similarly, plans for
the conventional linac were compared to those for the MR-Linac
with reduced margins to assess the effect of additional margin
reduction.
Conventionally fractionated plans were compared by evaluating
differences in several dose–volume metrics. Statistical significance
of the differences was evaluated with a paired t-test after confirm-
ing normal distribution using Lilliefors test [35]. Five metrics of
primary interest were chosen on a pre-hoc basis, because they
either have been shown to be associated with treatment toxicity,
they are highly influential during plan optimization or because ofced lung cancer with a 1.5 T MR-Linac – Effects of the magnetic field and
ted radiotherapyT MR-Linac –>. Radiother Oncol (2017), https://doi.org/
Table 1
Components contributing to the standard or reduced margins in left–right (LR), superior–inferior (SI) or anterior–posterior (AP) direction. Margins were calculated to ensure





LR SI AP LR SI AP
Contouring error 2.0 2.0 2.0 1.0 1.0 1.0
Difference in observed 4D tumour motion between planning and fraction 1.2 1.6 1.4 – – –
Total systematic error 2.3 2.6 2.4 1.0 1.0 1.0
Intrafractional baseline drift 1.5 1.7 1.8 1.5 1.7 1.8
Per-fraction localization error 2.0 2.0 2.0 1.0 1.0 1.0
Total random error 2.5 2.6 2.7 1.8 2.0 2.1
Beam penumbra 6.4 6.4 6.4 8.0 8.0 8.0
Total margin 6.4 7.1 6.8 2.8 2.9 2.9
Table 2
Notable differences in irradiation geometry between a conventional Versa HD linac
and the MR-Linac prototype, currently being developed by Elekta.
Versa HD MR-Linac prototype
Static magnetic field – 1.5 T
Nominal beam energy 6 MV 7 MV
Additional beam filtration – Cryostat
Source-to-axis distance 100.0 cm 142.5 cm
MLC leaf width at isocenter 5.0 mm 7.15 mm
Isocenter position relative to patient Variable Fixed at bore centre
H.E. Bainbridge et al. / Radiotherapy and Oncology xxx (2017) xxx–xxx 3their potential sensitivity to the presence of the 1.5 T magnetic
field: Mean lung dose, the percentage volume of the lung receiving
17 Gy or more (lung V17Gy), which is derived from the V20Gy metric
in treatments with 2 Gy fractions, oesophagus V30Gy, heart V25Gy
and the maximum dose received by 2% of contoured skin (skin
D2%). The statistical significance level for these metrics was chosen
to be p = 0.01 after correcting for multiple testing using a Bonfer-
roni correction for a level of p = 0.05 [36]. An array of other
dose–volume metrics was investigated in an exploratory analysis
with a significance level of p = 0.05 without correcting for multiple
testing. In order to extensively investigate the effect of the mag-
netic field on doses at air-tissue-interfaces, we also investigated
the dose to distal lung tissue, defined as any healthy lung tissue
more than 5 cm from the ITV. Furthermore, we monitored the
R50 conformality constraint, defined as follows:
R50 ¼ V27:5GyITV
with V27:5Gy being the total volume receiving 27.5 Gy or more and
the dose homogeneity index HI, calculated as:
HI ¼ D5%
D95%
where D5% and D95% correspond to the dose level covering 5% and
95% of the ITV, respectively.
Isotoxic dose-escalated treatment plans were quantified by the
maximum number of deliverable fractions. The different treatment
approaches were compared with a paired t-test at a statistical sig-
nificance level of p = 0.05. Additionally, we recorded the OAR con-
straint that limited further target dose escalation.
Results
Effect of MR-Linac irradiation geometry and PTV margin reduction on
conventionally fractionated treatments
Statistically significant differences were found in several dose–
volume metrics when comparing the conventionally fractionated
treatment plans designed for the 1.5 T MR-Linac to those for the
Versa HD linac (see Fig. 1). However, in all investigated cases itPlease cite this article in press as: Bainbridge HE et al. Treating locally advanc
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objectives.
With regard to the lung, treatment plans with standard margins
for the conventional and MR-Linac display similar mean doses
(conventional linac: 14.9 Gy ± 0.6 Gy; MR-Linac: 14.9 Gy ± 0.5 Gy,
p = 0.78). MR-Linac plans with reduced margins showed signifi-
cantly lower doses (14.3 Gy ± 0.6 Gy, p = 0.004). No statistically sig-
nificant differences were found for the lung V17Gy metric
(conventional linac: 29.2% ± 1.2%; MR-Linac with standard mar-
gins: 29.7% ± 1.4%, p = 0.04; MR-Linac with reduced margins:
29.0% ± 1.8%, p = 0.62). Further dosimetric analysis revealed that
with both standard and reduced margins, mean dose to distal lung
tissue was higher on the MR-Linac than on the conventional linac.
Conversely, exposure of lung tissue close to the target was lower in
MR-Linac plans with reduced margins compared to conventional
linac plans. This is reflected in a decrease in the R50 conformality
metric for the MR-Linac plans, which is exemplarily shown for
one patient in Fig. 2.
We found statistically significant increases in both mean skin
dose and high skin dose (skin D2%) in the MR-Linac plans with stan-
dard margins in comparison to the conventional linac plans (skin
Dmean: conventional linac 4.3 ± 1.4 Gy; MR-Linac: 4.7 ± 1.5 Gy,
p < 0.001; skin D2: conventional linac: 28.5 ± 7.1 Gy; MR-Linac:
30.2 ± 1.4 Gy, p = 0.003). However, using reduced margins the
MR-Linac plans are similar to conventional linac plans for skin
Dmean (4.2 ± 1.3 Gy, p = 0.38) and have a significantly lower high
skin dose (26.6 ± 6.7 Gy, p = 0.009). We also observed reductions
in oesophageal V43Gy and oesophageal mean dose, heart V4Gy and
spinal canal near-maximum dose on the MR-Linac with reduced
margins. However, the largest dose differences occurred in cases
in which the OAR dose was substantially below the limiting plan-
ning constraint.Potential for isotoxic dose escalation using an MR-Linac
With standard PTV margins, the potential for target dose esca-
lation on the MR-Linac and conventional linac are similar (see
Table 3). However, using reduced PTV margins, it is possible to sig-
nificantly escalate target dose (p = 0.03). In 7 out of 10 patients,
planning with reduced margins for the MR-Linac enabled addi-
tional dose escalation between 1 and 4 fractions in comparison
to plans for the conventional linac. For the remaining 3 cases, 2
had equivalent dose escalation potential on the MR-Linac and con-
ventional linac, and 1 had decreased maximum prescription level
with the MR-Linac.
In 19 of 30 plans the lung dose constraint limited further dose
escalation, and in the remaining 11 plans the mediastinal envelope
dose constraint restricted further escalation. We found that
there was more inter- than intra-patient variability in the doseed lung cancer with a 1.5 T MR-Linac – Effects of the magnetic field and
ted radiotherapyT MR-Linac –>. Radiother Oncol (2017), https://doi.org/
Fig. 1. Differences in the investigated dose–volume metrics between the plans designed for the MR-Linac with either standard or reduced margins and the conventional linac.
Numerically positive differences mark an increase in the respective metric for the MR-Linac plans. Displayed are the first and third quartiles (boxes), medians (bands inside),
average values (crosses), standard deviations (whiskers) and outliers (circles).
Fig. 2. Dose distribution of the conventionally fractionated treatment plans for patient 1 displayed over an axial (left), coronal (central) and sagittal (right) slice of the average
phase of the 4DCT scan. Plans were created either for a conventional linac with standard margins (top row) or the MR-Linac with reduced margins (bottom row). Marked are
the ITV (red) as well as the 95% (blue), 50% (yellow) isodose contours. (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
Table 3
Maximum deliverable dose for each patient when designing treatment plans following the isotoxic trial protocol without maximum target dose cap. Plans were designed for the
conventional linac or the MR-Linac, with either standard or reduced PTV margins. The respective constraints limiting further target dose escalation, either mean lung dose (lung)
or maximum mediastinal envelope dose (med env) are also shown. Statistical significance was measured using a paired t-test.
Patient number Conventional linac (standard margins) MR-Linac (standard margins) MR-Linac (reduced margins)
CTV dose [Gy] Limiting constraint CTV dose [Gy] Limiting constraint CTV dose [Gy] Limiting constraint
1 81.0 lung 79.2 lung 86.4 med env
2 77.4 lung 75.6 lung 79.2 lung
3 86.4 lung 81.0 lung 93.6 lung
4 79.2 med env 77.4 med env 79.2 med env
5 73.8 lung 75.6 lung 75.6 lung
6 82.8 med env 81.0 med env 81.0 med env
7 81.0 lung 81.0 lung 82.8 med env
8 73.8 med env 73.8 med env 73.8 med env
9 77.4 lung 77.4 lung 79.2 lung
10 77.4 lung 77.4 lung 81.0 lung
Mean 79.0 78.8 81.2
Significance level 0.75 0.03
4 Treating locally advanced lung cancer with a 1.5 T MR-Linac
Please cite this article in press as: Bainbridge HE et al. Treating locally advanced lung cancer with a 1.5 T MR-Linac – Effects of the magnetic field and
irradiation geometry on conventionally fractionated and isotoxic dose-escalated radiotherapyT MR-Linac –>. Radiother Oncol (2017), https://doi.org/
10.1016/j.radonc.2017.09.009
H.E. Bainbridge et al. / Radiotherapy and Oncology xxx (2017) xxx–xxx 5escalation limiting constraint, which suggests that this was more
dependent on patient geometry than treatment modality.Discussion
In the first part of this study we investigated the effect of MR-
Linac irradiation geometry, including the presence of a 1.5 T mag-
netic field, and PTV margin reduction on conventionally fraction-
ated treatments for patients with LA NSCLC. Lung V17Gy, which is
derived from the V20Gy metric in treatments with 2 Gy fractions,
was similar for all treatment modalities. We highlight this finding
as all plans were specifically optimized to minimize this dose–vol-
ume metric, and because of the importance of V20Gy as indicator of
pneumonitis risk [37–39]. We did observe a minor increase in dose
to distal lung tissue for the MR-Linac plans in comparison to con-
ventional linac plans. These changes are likely caused by the elec-
tron return effect at the air-tissue-interfaces of chest wall and lung,
or mediastinum and lung. However, these changes are small and
compared to the V17Gy metric, are less likely to be clinically
relevant.
The observed increase in dose to skin in the MR-Linac plans
with standard margins are as expected from previous studies
[25,28,40]. However, the reduction of PTV margins from approxi-
mately 7 mm to 3 mm on the MR-Linac alleviated this effect, most
likely due to the smaller required size of the portal fields compen-
sating for the electron return effect. This most likely also caused
the reduction in dose to other OAR including oesophagus, heart
and spinal cord. However, it has to be emphasized that the largest
dose differences occurred in cases in which the OAR dose was sub-
stantially below the limiting planning constraint. For serial organs,
the constraints for the optimizer were not set to reduce OAR expo-
sure beyond a fixed threshold. Therefore, it is likely that with
increased weight on these constraints further sparing could be
seen at the expense of increased dose elsewhere.
In the second part of this work we investigated the influence of
the MR-Linac design on isotoxic dose-escalated treatments. With
standard margins the potential for target dose escalation was sim-
ilar on the MR-Linac and conventional linac. A reduction in PTV
margins on the MR-Linac facilitated dose escalation in 7 out of
10 patients in comparison to the Versa HD plans. Meta-analysis
data in LA NSCLC suggests that a 1 Gy BED increase in radiotherapy
dose results in approximately 4% relative improvement in survival
based on two- and five-year survival data (median trial BED
74.67 Gy) [41]. Therefore, treating LA NSCLC on a MR-Linac may
provide a survival advantage for some patients.
To our knowledge this is the first work specifically investigating
the effect of MRI-guided treatment systems on radical radiother-
apy for LA NSCLC patients. Wooten et al. investigated the quality
of treatments delivered with the ViewRay system (ViewRay Inc.,
Oakwood Village, OH, USA), which combines three Cobalt-60
sources with MR imaging at 0.35 T field strength [42]. Their study
includes six patients with thoracic tumours and they display the
dosimetric differences for one patient with a centrally located lung
tumour. Overall in these patients they found a significant increase
in OAR dose (lung Dmean and heart Dmax) when designing plans for
the ViewRay system, particularly in the low-dose range <20 Gy, but
they did not report on skin dose metrics. We planned with a 1.5 T
magnetic field, and with equivalent margins observed no signifi-
cant increase in lung Dmean or heart metrics with the MR-Linac,
but did similarly observe an increase in lower doses to lung.
The margin reductions investigated in this study are one of the
potential advantages to be gained by the envisioned adaptive
workflow enabled by MRI-guided treatment machines. However,
it is not possible to identify the entire potential benefit with our
deployed methodology. In this work, we designed and evaluatedPlease cite this article in press as: Bainbridge HE et al. Treating locally advanc
irradiation geometry on conventionally fractionated and isotoxic dose-escala
10.1016/j.radonc.2017.09.009the treatment plans on the same average CT scan. This approach
does not consider possible inter- or intra-fractional changes in
patient anatomy, including shifting of air-tissue interface, which
could have an increased impact in the presence of a magnetic field.
However, another study using 4D dose reconstruction has not
found a pronounced effect of moving lung-tissue interfaces in real-
istic patient geometries for early-stage NSCLC [28]. In the future,
the ability to re-plan the treatment prior to each fraction as well
as dynamically adapting the treatment to target motion based on
high soft-tissue contrast MR images will likely further increase
normal-tissue sparing and, in the context of isotoxic protocols,
enable further target dose escalation.
In summary, this study has shown that it is feasible to design
clinically acceptable treatment plans for conventionally fraction-
ated as well as isotoxic dose-escalated radiotherapy for LA NSCLC
patients with a 1.5 T MR-Linac. When incorporating the potential
for PTV margin reduction facilitated by the advantageous imaging
capabilities of the MR-Linac, there is scope for OAR sparing and iso-
toxic target dose escalation in comparison to plans generated for a
conventional linac.
Acknowledgments
Research at The Institute of Cancer Research is supported by
Cancer Research UK under programmes C33589/A19727, C33489/
A19908 and C347/A18365. We acknowledge NHS funding to the
NIHR Biomedical Research Centre at The Royal Marsden and The
Institute of Cancer Research.
Conflict of interest
The Institute of Cancer Research is part of the Elekta MR-Linac Con-
sortium and we acknowledge financial and technical support from
Elekta AB under a research agreement. However, the sponsors had
no part in the design or execution of the study.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.radonc.2017.09.
009.
References
[1] Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus
sequential radiochemotherapy in locally advanced non - small-cell lung
cancer. J Clin Oncol 2010;28:2181–90.
[2] Machtay M, Paulus R, Moughan J, et al. Defining local-regional control and its
importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol
2012;7:716–22.
[3] Christodoulou M, Bayman N, McCloskey P, Rowbottom C, Faivre-Finn C. New
radiotherapy approaches in locally advanced non-small cell lung cancer. Eur J
Cancer 2014;50:525–34.
[4] Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy
(HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257
patients in a Japanese multi-institutional study. J Thoracic Oncol 2007;2:
S94–S100.
[5] Faivre-Finn C. Dose escalation in lung cancer: have we gone full circle? Lancet
Oncol 2015;16:125–7.
[6] Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose
conformal radiotherapy with concurrent and consolidation carboplatin plus
paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-
small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p.
Lancet Oncol 2015;16:187–99.
[7] De Ruysscher D, Van Baardwijk A, Steevens J, et al. Individualised isotoxic
accelerated radiotherapy and chemotherapy are associated with improved
long-term survival of patients with stage III NSCLC: A prospective population-
based study. Radiother Oncol 2012;102:228–33.
[8] Landau DB, Hughes L, Baker A, et al. IDEAL-CRT: A phase I/II trial of isotoxic
dose-escalated radiotherapy and concurrent chemotherapy in patients with
stage II/III non-small cell lung cancer. Int J Radiat Oncol Biol Phys.
2016;95:1367–77.ed lung cancer with a 1.5 T MR-Linac – Effects of the magnetic field and
ted radiotherapyT MR-Linac –>. Radiother Oncol (2017), https://doi.org/
6 Treating locally advanced lung cancer with a 1.5 T MR-Linac[9] van Baardwijk A, Reymen B, Wanders S, et al. Mature results of a phase II trial
on individualised accelerated radiotherapy based on normal tissue constraints
in concurrent chemo-radiation for stage III non-small cell lung cancer. Eur J
Cancer (Oxford, England: 1990) 2012;48:2339–46.
[10] van Baardwijk A, Wanders S, Boersma L, et al. Mature results of an
individualized radiation dose prescription study based on normal tissue
constraints in stages I to III non-small-cell lung cancer. J Clin Oncol
2010;28:1380–6.
[11] Warren M, Webster G, Ryder D, Rowbottom C, Faivre-Finn C. An isotoxic
planning comparison study for stage II-III non-small cell lung cancer: is
intensity-modulated radiotherapy the answer? Clin Oncol 2014;26:461–7.
[12] Kwint M, Conijn S, Schaake E, et al. Intra thoracic anatomical changes in lung
cancer patients during the course of radiotherapy. Radiother Oncol
2014;113:392–7.
[13] Kataria T, Gupta D, Bisht SS, et al. Adaptive radiotherapy in lung cancer:
dosimetric benefits and clinical outcome. Br J Radiol 2014;1038:20130643.
[14] Fallone BG, Murray B, Rathee S, et al. First MR images obtained during
megavoltage photon irradiation from a prototype integrated linac-MR system.
Med Phys 2009;36:2084–8.
[15] Keall PJ, Barton M, Crozier S, on behalf of the Australian MRI-Linac Program
including contributors from Ingham Institute Illawarra Cancer Care Centre
Liverpool Hospital Stanford University Universities of Newcastle Queensland
Sydney Western Sydney and Wollongong. The Australian magnetic resonance
imaging-linac program. Semin Radiat Oncol 2014;24:203–6.
[16] Raaymakers BW, Lagendijk JJ, Overweg J, et al. Integrating a 1.5 T MRI scanner
with a 6 MV accelerator: proof of concept. Phys Med Biol 2009;54:N229–37.
[17] Mutic S, Dempsey JF. The ViewRay system: magnetic resonance-guided and
controlled radiotherapy. Semin Radiat Oncol 2014;24:196–9.
[18] Aoyama H, Shirato H, Nishioka T, et al. Magnetic resonance imaging system for
three-dimensional conformal radiotherapy and its impact on gross tumor
volume delineation of central nervous system tumors. Int J Radiat Oncol Biol
Phys 2001;50:821–7.
[19] Yeung AR, Vargas CE, Falchook A, et al. Dose-volume differences for computed
tomography and magnetic resonance imaging segmentation and planning for
proton prostate cancer therapy. Int J Radiat Oncol Biol Phys 2008;72:1426–33.
[20] Chuter R, Prestwich R, Bird D, et al. The use of deformable image registration to
integrate diagnostic MRI into the radiotherapy planning pathway for head and
neck cancer. Radiother Oncol 2017;122:229–35.
[21] Raaymakers BW, Raaijmakers AJE, Kotte ANTJ, Jette D, Lagendijk JJW.
Integrating a MRI scanner with a 6 MV radiotherapy accelerator: dose
deposition in a transverse magnetic field. Phys Med Biol 2004;49:4109–18.
[22] Raaijmakers AJ, Raaymakers BW, Lagendijk JJ. Experimental verification of
magnetic field dose effects for the MRI-accelerator. Phys Med Biol
2007;52:4283–91.
[23] Raaijmakers AJ, Raaymakers BW, Lagendijk JJ. Integrating a MRI scanner with a
6 MV radiotherapy accelerator: dose increase at tissue-air interfaces in a
lateral magnetic field due to returning electrons. Phys Med Biol
2005;50:1363–76.
[24] Kirkby C, Murray B, Rathee S, Fallone BG. Lung dosimetry in a linac-MRI
radiotherapy unit with a longitudinal magnetic field. Med Phys
2010;37:4722–32.
[25] Yang YM, Geurts M, Smilowitz JB, Sterpin E, Bednarz BP. Monte Carlo
simulations of patient dose perturbations in rotational-type radiotherapy
due to a transverse magnetic field: a tomotherapy investigation. Med Phys
2015;42:715–25.Please cite this article in press as: Bainbridge HE et al. Treating locally advan
irradiation geometry on conventionally fractionated and isotoxic dose-escala
10.1016/j.radonc.2017.09.009[26] Merna C, Rwigema JC, Cao M, et al. A treatment planning comparison between
modulated tri-cobalt-60 teletherapy and linear accelerator-based stereotactic
body radiotherapy for central early-stage non-small cell lung cancer. Med
Dosim 2016;41:87–91.
[27] Oborn BM, Ge Y, Hardcastle N, Metcalfe PE, Keall PJ. Dose enhancement in
radiotherapy of small lung tumors using inline magnetic fields: a Monte Carlo
based planning study. Med Phys 2016;43:368.
[28] Menten MJ, Fast MF, Nill S, Kamerling CP, McDonald F, Oelfke U. Lung
stereotactic body radiotherapy with an MR-linac - Quantifying the impact of
the magnetic field and real-time tumor tracking. Radiother Oncol
2016;119:461–6.
[29] Park JM, Park SY, Kim HJ, Wu HG, Carlson J, Kim JI. A comparative planning
study for lung SABR between tri-Co-60 magnetic resonance image guided
radiation therapy system and volumetric modulated arc therapy. Radiother
Oncol 2016;120:279–85.
[30] Acharya S, Fischer-Valuck BW, Kashani R, et al. Online magnetic resonance
image guided adaptive radiation therapy: first clinical applications. Int J Radiat
Oncol Biol Phys 2016;94:394–403.
[31] van Herk M, Remeijer P, Rasch C, Lebesque JV. The probability of correct target
dosage: dose-population histograms for deriving treatment margins in
radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:1121–35.
[32] Guckenberger M, Krieger T, Richter A, et al. Potential of image-guidance, gating
and real-time tracking to improve accuracy in pulmonary stereotactic body
radiotherapy. Radiother Oncol 2009;91:288–95.
[33] Haslett K, Franks K, Hanna GG, et al. Protocol for the isotoxic intensity
modulated radiotherapy (IMRT) in stage III non-small cell lung cancer
(NSCLC): a feasibility study. BMJ Open 2016;6:e010457.
[34] Hissoiny S, Ozell Bt, Bouchard H, Després P. GPUMCD: a new GPU-oriented
Monte Carlo dose calculation platform. Med Phys 2011;38:754–64.
[35] Lilliefors HW. On the Kolmogorov-Smirnov test for normality with mean and
variance unknown. J Am Stat Assoc 1967;62:399–402.
[36] Dunn OJ. Multiple comparisons among means. J Am Stat Assoc 1961;56:52–64.
[37] Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the
lung. Int J Radiat Oncol Biol Phys 2010;76:S70–6.
[38] Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after
chemoradiation therapy for lung cancer: an international individual patient
data meta-analysis. Int J Radiat Oncol Biol Phys 2013;85:444–50.
[39] Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy
technique for locally advanced non-small-cell lung cancer: a secondary
analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin
Oncol 2017;35:56–62.
[40] van Heijst TC, den Hartogh MD, Lagendijk JJ, van den Bongard HJ, van Asselen
B. MR-guided breast radiotherapy: feasibility and magnetic-field impact on
skin dose. Phys Med Biol 2013;58:5917–30.
[41] Machtay M, Bae K, Movsas B, et al. Higher biologically effective dose of
radiotherapy is associated with improved outcomes for locally advanced non-
small cell lung carcinoma treated with chemoradiation: an analysis of the
Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys
2012;82:425–34.
[42] Wooten HO, Green O, Yang M, et al. Quality of intensity modulated radiation
therapy treatment plans using a 60Co magnetic resonance image guidance
radiation therapy system. Int J Radiat Oncol Biol Phys 2015;92:771–8.ced lung cancer with a 1.5 T MR-Linac – Effects of the magnetic field and
ted radiotherapyT MR-Linac –>. Radiother Oncol (2017), https://doi.org/
